Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 6.06
SPHS's Cash to Debt is ranked higher than
73% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. SPHS: 6.06 )
SPHS' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 6.06

F-Score: 4
Z-Score: -2.18
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -195.80
SPHS's Operating margin (%) is ranked higher than
64% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. SPHS: -195.80 )
SPHS' s 10-Year Operating margin (%) Range
Min: -300   Max: -106.67
Current: -195.8

-300
-106.67
Net-margin (%) -222.98
SPHS's Net-margin (%) is ranked higher than
63% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -69.57 vs. SPHS: -222.98 )
SPHS' s 10-Year Net-margin (%) Range
Min: -300   Max: -106.67
Current: -222.98

-300
-106.67
ROE (%) -91.97
SPHS's ROE (%) is ranked higher than
58% of the 877 Companies
in the Global Biotechnology industry.

( Industry Median: -28.59 vs. SPHS: -91.97 )
SPHS' s 10-Year ROE (%) Range
Min: -2308.71   Max: -8.7
Current: -91.97

-2308.71
-8.7
ROA (%) -64.24
SPHS's ROA (%) is ranked higher than
58% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. SPHS: -64.24 )
SPHS' s 10-Year ROA (%) Range
Min: -157.85   Max: -8.51
Current: -64.24

-157.85
-8.51
ROC (Joel Greenblatt) (%) -15761.43
SPHS's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. SPHS: -15761.43 )
SPHS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18300   Max: -2275.11
Current: -15761.43

-18300
-2275.11
Revenue Growth (%) -25.30
SPHS's Revenue Growth (%) is ranked higher than
65% of the 646 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SPHS: -25.30 )
SPHS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -25.3
Current: -25.3

EBITDA Growth (%) -18.10
SPHS's EBITDA Growth (%) is ranked higher than
67% of the 621 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. SPHS: -18.10 )
SPHS' s 10-Year EBITDA Growth (%) Range
Min: -31   Max: 72.9
Current: -18.1

-31
72.9
EPS Growth (%) -16.30
SPHS's EPS Growth (%) is ranked higher than
70% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. SPHS: -16.30 )
SPHS' s 10-Year EPS Growth (%) Range
Min: -28.9   Max: 70.5
Current: -16.3

-28.9
70.5
» SPHS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SPHS Guru Trades in Q3 2013

Jean-Marie Eveillard 250,000 sh (New)
» More
Q4 2013

SPHS Guru Trades in Q4 2013

Jean-Marie Eveillard 250,000 sh (unchged)
» More
Q1 2014

SPHS Guru Trades in Q1 2014

Jean-Marie Eveillard 250,000 sh (unchged)
» More
Q2 2014

SPHS Guru Trades in Q2 2014

Jean-Marie Eveillard 250,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SPHS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-09-30 New Buy$4.15 - $14.3 $ 2.87-66%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
SPHS's P/B is ranked higher than
92% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. SPHS: 1.80 )
SPHS' s 10-Year P/B Range
Min: 1.8   Max: 6.29
Current: 1.8

1.8
6.29
EV-to-EBIT -0.78
SPHS's EV-to-EBIT is ranked higher than
69% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPHS: -0.78 )
SPHS' s 10-Year EV-to-EBIT Range
Min: 21.5   Max: 41
Current: -0.78

21.5
41
Current Ratio 6.94
SPHS's Current Ratio is ranked higher than
84% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. SPHS: 6.94 )
SPHS' s 10-Year Current Ratio Range
Min: 0.6   Max: 118.33
Current: 6.94

0.6
118.33
Quick Ratio 6.94
SPHS's Quick Ratio is ranked higher than
86% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. SPHS: 6.94 )
SPHS' s 10-Year Quick Ratio Range
Min: 0.6   Max: 118.33
Current: 6.94

0.6
118.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.01
SPHS's Price/Net Cash is ranked higher than
97% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 80.40 vs. SPHS: 2.01 )
SPHS' s 10-Year Price/Net Cash Range
Min: 1.53   Max: 14.62
Current: 2.01

1.53
14.62
Price/Net Current Asset Value 2.01
SPHS's Price/Net Current Asset Value is ranked higher than
97% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 41.80 vs. SPHS: 2.01 )
SPHS' s 10-Year Price/Net Current Asset Value Range
Min: 1.53   Max: 13.76
Current: 2.01

1.53
13.76
Price/Tangible Book 1.78
SPHS's Price/Tangible Book is ranked higher than
94% of the 984 Companies
in the Global Biotechnology industry.

( Industry Median: 8.73 vs. SPHS: 1.78 )
SPHS' s 10-Year Price/Tangible Book Range
Min: 1.36   Max: 9.88
Current: 1.78

1.36
9.88
Earnings Yield (Greenblatt) 6.00
SPHS's Earnings Yield (Greenblatt) is ranked higher than
79% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SPHS: 6.00 )
SPHS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.4   Max: 11.8
Current: 6

2.4
11.8
Forward Rate of Return (Yacktman) -121.03
SPHS's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -10.16 vs. SPHS: -121.03 )
SPHS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -34.4   Max: -19.9
Current: -121.03

-34.4
-19.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:SHS.Canada, BFF1.Germany
Sophiris Bio Inc was formed in May 2003 under the predecessor to the Business Corporations Act by the amalgamation of Stratos Biotechnologies Inc., Nucleus BioScience Inc. and Brightwave Ventures Inc. It began operations on January 11, 2002. The Company's operations were initially located in Vancouver, British Columbia. Effective April 2, 2012, the Company changed its name from Protox Therapeutics Inc. to Sophiris Bio Inc. The Company is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of urological diseases. It is currently developing PRX302 for treatment of the symptoms of benign prostatic hyperplasia. BPH is a non-cancerous enlargement of the prostate gland that commonly affects men who are age 50 and older. The Company expects that PRX302 will compete with the current treatment options for the symptoms of BPH, which include oral drug therapy and surgery. Its business and operations are subject to a variety of U.S. federal, state and local, and foreign supranational, national, provincial and municipal laws, regulations and trade practices. As of December 31, 2012, it had nine full-time employees and one part-time employee.
» More Articles for SPHS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: STRA, IMI, HXM, SPHS Jan 06 2014 
From The Land of What If - Smart Proteins and Debt Collectors Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
Sophiris Bio to Present at the 13th Annual BIO Investor Forum Sep 30 2014
Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign... Sep 02 2014
Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights Aug 07 2014
Sophiris Bio files to sell 3.41M shares of common stock for holders May 28 2014
Sophiris Bio to Present at the Jefferies 2014 Global Healthcare Conference May 22 2014
Sophiris Bio announces stock purchase agreement with Aspire Capital May 19 2014
Sophiris Enters into Common Stock Purchase Agreement with Aspire Capital to Support Proof of Concept... May 19 2014
Sophiris Bio reports Q1 EPS 52c, one estimate (50c) May 13 2014
Sophiris Bio Reports First Quarter Financial Results May 13 2014
Wall Street Transcript Interview with Randall E. Woods, the President and CEO of Sophiris Bio Inc.... Apr 25 2014
Sophiris Bio to Present at the 13th Annual Needham Healthcare Conference Mar 25 2014
Sophiris Adds Gerald T. Proehl to its Board of Directors Mar 20 2014
Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational... Mar 14 2014
Sophiris Bio Reports Fourth Quarter and Full Year 2013 Financial Results and Key Operational... Mar 13 2014
Sophiris Bio to Present at the Cowen and Company 34th Annual Health Care Conference Feb 26 2014
Sophiris Bio to Present at the 2014 Leerink Global Healthcare Conference Feb 03 2014
3 Health Care Stocks Under $10 Moving Higher Jan 10 2014
Sophiris Bio: Recent Price Action Offers An Attractive Entry Point Dec 31 2013
4 Stocks Under $10 Moving Higher Nov 20 2013
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights Nov 12 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK